Dirt Cheap Stocks to Buy With $1,000 Right Now

Hormel (HRL) yields ~5.2% and General Mills (GIS) yields ~6.5%, highlighting a large value/dividend opportunity as both stocks trade cheaply versus historical norms. GLP-1 drug adoption and tighter consumer budgets are pressuring sales mix, but price-to-sales and price-to-book are below five-year averages and managements are pursuing innovation, acquisitions and cost cuts. Both companies have long dividend track records (Hormel: Dividend King; General Mills: 127 years of paying dividends), and a $1,000 investment would buy roughly 45 shares of Hormel or 26 shares of General Mills today.

Analysis

GLP-1 driven behaviour change is less a binary volume collapse and more a rapid, sectoral reshuffle: calorie reduction concentrates spending into higher-per-protein SKUs, single-serve formats, and premium prepared foods. That favors suppliers with scalable protein platforms, cold-chain flexibility, and nimble NPD pipelines; it penalizes commoditized, price-competitive cereal and boxed-meal SKUs where private-label can grab share within a razor-thin basket of necessities.

Second-order supply effects matter: if total caloric throughput softens, grain and vegetable oil demand falls but animal-protein mix shifts may push different feed baskets (e.g., more poultry vs beef), creating idiosyncratic margin tailwinds for processors with the right product mix. Cost trajectories (corn/soy/hog prices) and freight/cold-storage utilization will therefore be as important to near-term EBIT as topline unit trends — margin recovery can arrive from both lower inputs and higher mix.

Key timing/catalysts: expect visible sales/mix inflection points in the next 2–6 quarters as companies roll out reformulations and premium SKUs; material reversal would require either a sharp slowdown in GLP-1 adoption (12–24 months) or a macro shock that destroys premiumization (3–6 months). Consensus is overstating permanent volume loss and understating firms’ ability to reallocate marketing capex and M&A into growth verticals (pet, snack protein, convenient meals), making a defensive-but-active position the higher-expected-return route versus a pure cyclical short.

Key Decisions for Investors

• Initiate overweight HRL (30–90 day entry window) sized 1–2% NAV with 12-month target total return +25% (capital + dividends). Rationale: protein mix optionality + operating leverage to falling commodity costs. Risk control: buy 1-year 15% OTM puts equal to 30% notional to cap downside; stop-loss at -18% on equity leg.
• Pair trade: Long HRL / Short GIS at a 1.5:1 notional ratio for 6–12 months to express protein-premium vs legacy-cereal exposure. Target pair alpha +15% if mix shift accelerates; risk if GIS’s pet/adjacencies outperform—set rebalancing alerts at +/-10% divergence and cap max drawdown at 12% on net position.
• Options idea for yield capture: Sell HRL 6–9 month covered calls at ~20% OTM on ~50% of position to monetize current income profile while retaining upside to a similar 20–25% window. If HRL rerates quickly, buy back into earnings gap; if it grinds lower, use premium to buy additional shares on weakness.
• Event hedge: Buy a 6–12 month consumer staples ETF put (or long volatility exposure) sized to cover ~30% of staples exposure ahead of the next quarterly print cycle and FDA/coverage updates on GLP-1s. This is cheap insurance against headlines that could pause premiumization and accelerate budget cuts across staples.
• If seeking contrarian long on GIS specifically, use a collar: buy GIS outright and buy a 12-month 20% OTM put while selling a 12-month 30% OTM call. This limits upside but protects through the restructuring turnaround window (12–24 months) and finances downside protection via call premium.